Overview

Vaccination of High Risk Breast Cancer Patients

Status:
Completed

Trial end date:
2023-01-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor (ER)-positive, HER2-negative breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Arkansas

Treatments:

Cyclophosphamide
Docetaxel
Doxorubicin
Monatide (IMS 3015)